Domperidone is a small molecule that works as a Dopamine D2 Receptor Antagonist.[2] It is being investigated across 6 indications, with its most advanced program in Phase 3.[1]
Domperidone is one of 106 small molecule programs targeting Diabetes Mellitus. It is currently in Phase 3.
Indications
Total Trials
Active Trials
Competitors
Pipeline
Competition
172 competitors in Chronic Kidney Disease
Domperidone
Nalfurafine Hydrochloride
Uloric
Sovaldi
Glucotrol
Vemlidy
Lorelco
Activase
Flomax
Verquvo
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Sources
Details